1-beta-D-Arabinofuranosyl-cytosine Induces Chromosomal Breaks in vitro.
- Author:
In sang JEON
1
Author Information
1. Department of Pediatrics, Gil Medical Center, Gachon Medical School, Inchon, Korea. isjeon@ghil.com
- Publication Type:In Vitro ; Original Article
- Keywords:
1beta-D-Arabinofuranosy1-cytosine(Ara-C);
Chromosomal break;
Fragile site;
Neoplasm
- MeSH:
Caffeine;
Chromosome Breakage*;
Chromosome Breakpoints;
Cytarabine;
Female;
Folic Acid;
Genes, jun;
Humans;
Incidence;
Male;
Metaphase;
Oncogenes;
S Phase;
T-Lymphocytes
- From:Journal of the Korean Pediatric Society
2003;46(12):1186-1193
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Fragile sites are points on chromosomes which tend to break non-randomly when exposed to specific chemical agents or conditions of tissue culture. The chromosomal break induced by the antineoplastic drug, 1-beta-D-arabinofuranosyl-cytosine(Ara-c), was investigated to study the laboratory conditions in which the incidence of chromosomal break could be enhanced. Besides, the fragile sites induced by Ara-C were investigated and compared to the already known locations of the specific chromosomal alterations observed in specific neoplasms. METHODS: T-lymphocytes from theree normal males and three females were cultured for 48 hours. Cells from each individual were exposed to the Ara-C for an additional 24 hours. After the caffeine was added during the last six hours culture, the metaphase chromosomes were prepared following the conventional method. A site was considered fragile if it was found to break two or more per 100 chromosomal breaks in more than four of six individuals tested. RESULTS: Ara-C induced 252.1 chromosomal breaks per 100 mitotic cells and this result was significantly higher than that of the control, which induced 25.2 breaks(P<0.05). The incidence of the chromosomal break by Ara-C was higher, if cultured in the MEM-FA, which has no folic acid, than in the RPMI 1640 which contains enough folic acid(P<0.05). The most common break site by Ara-C was 3p14.2(FRA3B). There were 20 fragile sites induced by Ara-C. Among these 20 fragile sites, seven coincided with the locations of the mapped oncogenes, JUN, SKI, REL, N-MYC, FHIT, MET, ETS-1, and FOS. CONCLUSIONS: S phase specific chemotherapeutic agent, Ara-C, induced the expression of the chromosomal fragile sites effectively using the T-lymphocyte in vitro. Some of the fragile sites by Ara-C highly coincided with the oncogenes and neoplasm specific chromosome breakpoints. In this regard, the fragile sites reported here could provide the unknown neoplasm related chromosomal alternation points.
